Argenx price target lowered to $890 from $925 at RBC Capital

RBC Capital lowered the firm’s price target on Argenx (ARGX) to $890 from $925 but keeps an Outperform rating on the shares after its Q4 results. The firm “remains buyers” given its expectations that Vyvgart’s uptake doubles from here in approved indications, adding it can’t think of many Biotech companies with 20 Phase II/III trials ongoing with relatively high probability of success, the analyst tells investors in a research note.